REFERENCES
1. Koskas M, Amant F, Mirza MR, Creutzberg CL. Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet 2021;155 Suppl 1:45-60.
2. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet 2021;155 Suppl 1:28-44.
3. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021;31:12-39.
4. Murali R, Davidson B, Fadare O, et al. High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol 2019;38 Suppl 1:S40-63.
5. Brooks RA, Fleming GF, Lastra RR, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 2019;69:258-79.
6. Bendifallah S, Ilenko A, Daraï E. High risk endometrial cancer: clues towards a revision of the therapeutic paradigm. J Gynecol Obstet Hum Reprod 2019;48:863-71.
7. Randall ME, Filiaci V, McMeekin DS, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol 2019;37:1810-8.
8. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816-23.
9. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a gynecologic oncology group study. Gynecol Oncol 2009;112:543-52.
10. Barton MB, Frommer M, Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol 2006;7:584-95.
11. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2004;59:168-73.
12. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer 2010;46:2422-31.
13. Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 2019;380:2317-26.
14. Tung HJ, Huang HJ, Lai CH. Adjuvant and post-surgical treatment in endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2022;78:52-63.
15. Luo L, Shi W, Zhigang Z, Kollmeier M, Alektiar K, Tsai C. Association of delayed adjuvant therapy and overall survival in early stage endometrial cancer. J Clin Oncol 2017;99:E301.
16. Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011;377:127-38.
17. Johnson N, Miles T, Bailey D, et al. Delays in treating endometrial cancer in the South West of England. Br J Cancer 2011;104:1836-9.
18. Cattaneo R 2nd, Hanna RK, Jacobsen G, Elshaikh MA. Interval between hysterectomy and start of radiation treatment is predictive of recurrence in patients with endometrial carcinoma. Int J Radiat Oncol Biol Phys 2014;88:866-71.
19. Neron M, Lambaudie E, Thezenas S, et al. Impact of time to radiation therapy in adjuvant settings in endometrial carcinoma: a multicentric retrospective study. Eur J Obstet Gynecol Reprod Biol 2020;247:121-6.
20. Dolly D, Mihai A, Rimel BJ, et al. A delay from diagnosis to treatment is associated with a decreased overall survival for patients with endometrial cancer. Front Oncol 2016;6:31.
21. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019;20:1273-85.
22. Lu SM, Chang-Halpenny C, Hwang-Graziano J. Sequential versus “sandwich” sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma. Gynecol Oncol 2015;137:28-33.
